The association with City of Hope gives great credibility to the company.
Independent of the company, we know that City of Hope continue their research with CAR T....in order to help many cancer patients around the world.
Here again (at bottom) is a link to an excellent interview from the CEO last week. Specific mention is made of planning being undertaken, for our drug to move into a Phase 2 FDA GBM registration trial.
These comments, from the CEO, and backed by other highly creditable people , within the company - can only be made, with advice direct from City of Hope. The fact plans are underway for the phase 2, confirms the success and efficacy of the drug so far ...at least to this stage. It is impossible to think otherwise.
But I think its gets alot better, and that is the reason for the link again.
If you go direct to the 22 m 16 sec stage of the video........ the CEO discusses a planned basket trial for our drug in lung, prostrate, melanoma and colorectal cancer. Once again, this sort of discussion can only come from City of Hope.
In fact, this is what City of Hope said about this drug (our drug) last year, in relation to non GBM solid cancer mutations....... And now we have the basket trial mentioned, in some of the most common cancer diseases.
_______________________________________________________ SCORPION VENOM USED IN CAR T TREATMENT FOR GLIOBLASTOMA
CLTX-CAR T
The so-called CLTX-CAR T was deployed at glioblastoma resections in the City of Hope Medical Centre in Los Angeles (USA). It became clear that the CLTX-CAR T bound to a large spectrum of glioblastoma cells. It did so more than other CAR T cell therapies that are currently being considered, such as those using the antigen IL13Rα2, HER2, EphA2 or EGFR. SOURCES
